Sponsor Study ID:
An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
(MUSC NetID required for document access)